Enasidenib Nitroso Impurity 2
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds.Enasidenib is used to treat acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation in patients who have not responded to other treatments or to those whose cancer has come back after treatment.Enasidenib Nitroso Impurity 2 is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Enasidenib Nitroso Impurity 2 CAS NO: NA chemically represented as N-(4-((2-Hydroxy-2-methylpropyl)(nitroso)amino)-6-(6-(trifluoromethyl)pyridin-2-yl)-1,3,5-triazin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)nitrous amide. Synchemia is the leading manufacturing and exporter of Enasidenib Nitroso Impurity 2 . We supply Enasidenib Nitroso Impurity 2 with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0143332 |
| CAS No | NA |
| Mol.F. | C16H20N43O3 |
| Mol.Wt. | 316.36 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143333 |
| CAS No | NA |
| Mol.F. | C15H20N4O2 |
| Mol.Wt. | 288.35 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143334 |
| CAS No | NA |
| Mol.F. | C23H22N4O4 |
| Mol.Wt. | 418.45 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143335 |
| CAS No | NA |
| Mol.F. | C15H20N4O2 |
| Mol.Wt. | 288.35 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143336 |
| CAS No | 84174-24-3 |
| Mol.F. | C8H9N3O3 |
| Mol.Wt. | 195.18 g/mole |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0143337 |
| CAS No | 122021-01-6 |
| Mol.F. | C16H24N2O3 |
| Mol.Wt. | 292.4 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143338 |
| CAS No | NA |
| Mol.F. | C8H8N2O3 |
| Mol.Wt. | 180.16g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143339 |
| CAS No | NA |
| Mol.F. | C9H10N2O3 |
| Mol.Wt. | 194.19 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143340 |
| CAS No | NA |
| Mol.F. | C8H7ClN2O3 |
| Mol.Wt. | 214.61 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143341 |
| CAS No | NA |
| Mol.F. | C10H10N2O4 |
| Mol.Wt. | 222.20 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143342 |
| CAS No | NA |
| Mol.F. | C8H7ClN2O2 |
| Mol.Wt. | 198.61 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143343 |
| CAS No | NA |
| Mol.F. | C16H15N3O5 |
| Mol.Wt. | 329.31 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143344 |
| CAS No | NA |
| Mol.F. | C16H15N3O4 |
| Mol.Wt. | 313.31 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143345 |
| CAS No | NA |
| Mol.F. | C16H15N3O5 |
| Mol.Wt. | 329.31 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143346 |
| CAS No | NA |
| Mol.F. | C16H15N3O4 |
| Mol.Wt. | 313.31 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143347 |
| CAS No | NA |
| Mol.F. | C10H14N4O3 |
| Mol.Wt. | 238.2 g/mole |
| INV STATUS | UNDER SYNTHESIS |